The series C venture capital round that Tessera Therapeutics announced on 19 April – totaling more than $300m, the company said – shows that investors continue to be willing to invest large sums in novel biopharmaceutical technologies even while the means of exiting such investments are in doubt.
Mergers and acquisitions have not occurred at a brisk pace to date in 2022 and initial public offerings have been...






